Beximco Pharmaceuticals Limited
BXP.L · LSE
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Revenue | £44 | £39 | £35 | £29 |
| % Growth | 13.1% | 13.3% | 17.5% | – |
| Cost of Goods Sold | £25 | £22 | £19 | £16 |
| Gross Profit | £20 | £17 | £16 | £14 |
| % Margin | 44.2% | 43.6% | 45.6% | 47.2% |
| R&D Expenses | £0 | £0 | £0 | £0 |
| G&A Expenses | £1 | £1 | £1 | £1 |
| SG&A Expenses | £6 | £5 | £9 | £7 |
| Sales & Mktg Exp. | £5 | £5 | £8 | £6 |
| Other Operating Expenses | £5 | £4 | -£0 | -£0 |
| Operating Expenses | £11 | £10 | £9 | £7 |
| Operating Income | £9 | £7 | £7 | £7 |
| % Margin | 19.5% | 18.4% | 19.9% | 22.5% |
| Other Income/Exp. Net | -£1 | -£1 | -£0 | -£0 |
| Pre-Tax Income | £8 | £6 | £7 | £6 |
| Tax Expense | £2 | £2 | £2 | £1 |
| Net Income | £6 | £5 | £5 | £5 |
| % Margin | 13.1% | 11.8% | 14.8% | 17.4% |
| EPS | 13.07 | 10.34 | 11.48 | 11.49 |
| % Growth | 26.4% | -9.9% | -0.1% | – |
| EPS Diluted | 13.07 | 10.34 | 11.48 | 11.49 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £1 | £1 | £1 | £1 |
| Depreciation & Amortization | £2 | £2 | £2 | £0 |
| EBITDA | £11 | £9 | £8 | £7 |
| % Margin | 24% | 23.9% | 23.8% | 25% |